Omeros Corporation
OMERDrugs in Pipeline
12
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
OMER Earnings Report
EPS Est: $-0.27 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How OMER's past catalysts played out
Phenylephrine HCl
Unilateral Cataract Extraction
OMS103HP-S
Meniscal Tear
OMS302
Intraocular Lens Replacement
OMS103HP
Anterior Cruciate Ligament Reconstruction
OMS302-PE
Cataract Extraction
OMS906
Paroxysmal Nocturnal Hemoglobinuria
OMS302 Solution
Cataract
Biological: narsoplimab
Thrombotic Microangiopathies
OMS643762
Schizophrenia
OMS201
Urinary Calculi
OMS721
Thrombotic Microangiopathies
OMS906 study drug
Paroxysmal Nocturnal Hemoglobinuria
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Phenylephrine HCl | Phase 3 | Unilateral Cataract Extraction | - | - |
OMS103HP-S | Phase 3 | Meniscal Tear | - | - |
OMS302 | Phase 3 | Intraocular Lens Replacement | - | - |
OMS103HP | Phase 3 | Anterior Cruciate Ligament Reconstruction | - | - |
OMS302-PE | Phase 2 | Cataract Extraction | - | - |
OMS906 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
OMS302 Solution | Phase 2 | Cataract | - | - |
Biological: narsoplimab | Phase 2 | Thrombotic Microangiopathies | - | - |
OMS643762 | Phase 2 | Schizophrenia | - | - |
OMS201 | Phase 2 | Urinary Calculi | - | - |
OMS721 | Phase 2 | Thrombotic Microangiopathies | - | - |
OMS906 study drug | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Omeros Corporation's drug pipeline?→
CatalystAlert tracks 12 drug candidates in Omeros Corporation's (OMER) pipeline across Phase 3, Phase 2. Its lead program is Phenylephrine HCl (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Omeros Corporation's next FDA catalyst?→
Omeros Corporation's (OMER) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OMER biotech catalysts?→
Add OMER to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Omeros Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.